His grant - titled Multiomics and Antiretroviral Drug Exposure for assessing Metabolic Effects (MADE-FOR-ME) - will examine the interplay of antiretroviral pharmacology and metabolic effects that lead to downstream cardiovascular disease.
"People living with HIV are at an increased risk of developing aging-related comorbidities, such as cardiovascular disease, even with contemporary antiretroviral therapy. As we enter the fourth decade of antiretroviral therapy, there are uniquely 21st-century research problems that will require 21st-century solutions."
Dr. Devanathan's laboratory focuses on the clinical pharmacology of antiretrovirals and their disposition into biological matrices with the goal of understanding how antiretroviral pharmacology affects inflammatory processes related to HIV-associated comorbidities.
The grant awarded to Dr. Devanathan provides $2.6 million over 5 years.
